Dr. Karol is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105- Is this information wrong?
Summary
- Dr. Seth Karol is a pediatric hematologist/oncologist in Memphis, TN and is affiliated with St. Jude Children's Research Hospital. He received his medical degree from The Ohio State University College of Medicine and has been in practice as a pediatric oncologist since 2012. He has expertise in experienced acute lymphoblastic leukemia, acute myeloid leukemia, treatment side effects, early phase clinical trials, and pharmacogenomics.
Education & Training
- University of TennesseeFellowship, Pediatric Hematology/Oncology, 2012 - 2015
- Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2008 - 2011
- Ohio State University College of MedicineClass of 2008
Certifications & Licensure
- TN State Medical License 2012 - 2025
- OH State Medical License 2008 - 2012
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Start of enrollment: 2020 Sep 04
- Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma Start of enrollment: 2020 Oct 15
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.Xin Huang, Yizhen Li, Jingliao Zhang, Lei Yan, Huanbin Zhao, Liang Ding, Sheetal Bhatara, Xu Yang, Satoshi Yoshimura, Wenjian Yang, Seth E Karol, Hiroto Inaba, Charles...> ;Cancer Cell. 2024 Apr 8
- 1 citationsCOVID-19 in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma.Bodea, J., Patni, T., Angel, S., Wolf, J., Li, Y., Hashmi, S., Bhakta, N., Jeha, S., Karol, S., Ribeiro, R., Rubnitz, J., Pui, C., Hijano, D., Inaba, H.> ;JAMA Network Open. 2024 Feb 5
- Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.Maud Maillard, Rina Nishii, Wenjian Yang, Keito Hoshitsuki, Divyabharathi Chepyala, Shawn H R Lee, Jenny Q Nguyen, Mary V Relling, Kristine R Crews, Mark Leggas, Meenu...> ;Journal of the National Cancer Institute. 2024 May 8
- Join now to see all
Lectures
- Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- Venetoclax plus High-Dose Cytarabine with or Without Idarubicin Well Tolerated in Pediatric AMLMay 1st, 2020
- ASH Annual Meeting Highlights St. Jude ResearchDecember 6th, 2019
- Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AMLJune 14th, 2019
- Join now to see all
Hospital Affiliations
- St. Jude Children's Research HospitalMemphis, Tennessee
External Links
- St. Jude profilehttp://www.stjude.org/karol
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: